This is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication This medicinal product is for diagnostic use only and the approved indication is scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. Scintimun should not be used for the diagnosis of diabetic foot infection.
Therapeutic Area (MeSH)
ATC Code
V09HA03
ATC Item
technetium (99mTc) antigranulocyte antibody
Pharmacotherapeutic Group
Diagnostic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| besilesomab | N/A | Besilesomab |
EMA Name
Scintimun
Medicine Name
Scintimun
Aliases
N/ANo risk management plan link.
